Glioblastoma cancer stem cell-specific antigens (GSC antigens)

Glioblastoma cancer stem cell-specific antigens represent a heterogeneous group of surface and intracellular markers that identify glioblastoma stem cells (GSCs), a highly tumorigenic subpopulation within glioblastoma multiforme (GBM) responsible for tumor initiation, progression, and recurrence [1, 3]. These antigens include cell surface proteins such as CD133, CD44, and L1CAM, as well as intracellular markers like Nestin and transcription factors such as SOX2 and Nanog [1, 6]. They play essential roles in maintaining GSC stemness, self-renewal, and the ability to differentiate into various neural lineages [2, 9]. Therapeutic strategies targeting these antigens include active immunotherapy with dendritic cell vaccines (e.g., KROS 201, ICT-107), passive immunotherapy with CAR-T cells, and small molecule inhibitors of stemness-related signaling pathways like Notch and Wnt [3, 11, 13]. For instance, KROS 201 utilizes dendritic cells primed with these antigens to activate a patient's own T cells against the GSC population [11, 14]. However, the clinical application of these targets is hindered by the high degree of intratumoral heterogeneity and the potential for off-target effects on normal neural stem cells, which share many of these markers [4, 10, 12]. Consequently, effective treatment likely requires multi-antigen targeting and strategies to overcome the immunosuppressive microenvironment of the brain [10, 12].

Other names

Glioblastoma stem cell markersGSC markersBrain tumor stem cell antigensGSC-specific antigens

Dendritic cell-mediated T-cell activation, chimeric antigen receptor (CAR) T-cell targeting, and small molecule inhibition of self-renewal pathways.